Latest news with #Baclofen
Qatar Tribune
5 days ago
- Health
- Qatar Tribune
Sidra Medicine first hospital in ME to successfully perform Intraventricular Baclofen Therapy
Tribune News Network Doha Sidra Medicine, a member of Qatar Foundation, is the first hospital in the Middle East to successfully perform two Intraventricular Baclofen Therapies. The milestone highlights Sidra Medicine's commitment to pioneering advanced neurosurgical treatments for children and young people with severe movement disorders. The procedure was performed on two young people with Dystonia. Dystonia is a neurological condition that causes uncontrolled muscle contractions. Following the procedure at Sidra Medicine, both adolescents experienced a remarkable improvement in their condition, demonstrating the effectiveness of this innovative therapy. Dr. Ian Pople, chief of Neurosurgery at Sidra Medicine, who led the procedure and emphasised its significance, said: 'The neurosurgery performed on both patients was highly successful. Unlike traditional intrathecal Baclofen therapy, which delivers the drug into the spinal fluid via a pump in the lower back, the intraventricular approach administers the medication directly into the brain's ventricles, allowing for more effective treatment of severe dystonia affecting the entire body. This approach underscores the importance of integrating neurosurgical precision with rehabilitation, ensuring patients receive the most advanced care available.' Innovative Treatment Approach Intraventricular Baclofen Therapy begins with the placement of a ventricular reservoir to allow for a trial of Baclofen therapy. This minimally invasive procedure is performed in the operating room using neuronavigational equipment, and the patient stays overnight for monitoring. Once the surgical site has healed, the patient undergoes a three-day trial in the neurosurgical ward, where an external pump delivers Baclofen similarly to the fully implanted device. Regular assessments help determine the patient's response to the medication. If the trial is successful, a permanent Baclofen pump is implanted to provide continuous therapy. The dosage is gradually adjusted to optimise symptom control, significantly improving the patient's quality of life. Qatar's First Paediatric Movement Disorders Clinic Sidra Medicine features Qatar's first paediatric-focused Movement Disorders Clinic, offering advanced care for children and young people with spasticity (uncontrollable muscle stiffness) and dystonia. The clinic takes a multidisciplinary approach, with specialists in rehabilitation medicine, neurology, neurosurgery, and therapy. It provides surgical and non-surgical interventions for patients who have not responded to medications and conventional therapy. The clinic is a key part of Sidra Medicine's commitment to pioneering pediatric neurology care. Adam's Journey: A Life Transformed Adam was one of the young patients who underwent the groundbreaking Intraventricular Baclofen Therapies at Sidra Medicine. Speaking about the impact of the treatment, Adam's mother said, 'Before the surgery, Adam's condition affected nearly every part of his day. His limbs moved constantly, making it difficult for him to concentrate, rest, or participate in school like other children his age. 'After his surgery at Sidra Medicine and thanks to the Movement Disorders Clinic, Adam's movements began to settle, and he gained a level of control we had not seen in years. These small improvements transformed how he interacts with the world. It has brought hope back into our home, and I truly believe this procedure and the supporting rehabilitative support can help many more children like Adam.' Comprehensive Neurosurgical Care at Sidra Medicine Sidra Medicine's Neurosurgery Department specialises in treating a wide range of neurological conditions, including hydrocephalus, congenital abnormalities, brain and spinal tumours, epilepsy, craniofacial disorders, and spinal conditions. The hospital's use of cutting-edge technology, combined with a patient-centred approach, ensures that children receive world-class care tailored to their individual needs. For international inquiries about Sidra Medicine's Neurosurgery services, contact
Qatar Tribune
6 days ago
- Health
- Qatar Tribune
Sidra Medicine becomes first hospital in Middle East to successfully perform Intraventricular Baclofen Therapy
DOHA: Sidra Medicine, a member of Qatar Foundation, is the first hospital in the Middle East to successfully perform two Intraventricular Baclofen Therapies. The milestone highlights Sidra Medicine's commitment to pioneering advanced neurosurgical treatments for children and young people with severe movement disorders. The procedure was performed on two young people with Dystonia. Dystonia is a neurological condition that causes uncontrolled muscle contractions. Following the procedure at Sidra Medicine, both adolescents experienced a remarkable improvement in their condition, demonstrating the effectiveness of this innovative therapy. Dr Ian Pople, Chief of Neurosurgery at Sidra Medicine, who led the procedure and emphasized its significance said: "The neurosurgery performed on both patients was highly successful. Unlike traditional intrathecal Baclofen therapy, which delivers the drug into the spinal fluid via a pump in the lower back, the intraventricular approach administers the medication directly into the brain's ventricles, allowing for more effective treatment of severe dystonia affecting the entire body. This approach underscores the importance of integrating neurosurgical precision with rehabilitation, ensuring patients receive the most advanced care available." Intraventricular Baclofen Therapy begins with the placement of a ventricular reservoir to allow for a trial of Baclofen therapy. This minimally invasive procedure is performed in the operating room using neuronavigational equipment, and the patient stays overnight for monitoring. Once the surgical site has healed, the patient undergoes a three-day trial in the neurosurgical ward, where an external pump delivers Baclofen similarly to the fully implanted device. Regular assessments help determine the patient's response to the medication. If the trial is successful, a permanent Baclofen pump is implanted to provide continuous therapy. The dosage is gradually adjusted to optimize symptom control, significantly improving the patient's quality of life. Sidra Medicine features Qatar's first pediatric-focused Movement Disorders Clinic, offering advanced care for children and young people with spasticity (uncontrollable muscle stiffness) and dystonia. The clinic takes a multidisciplinary approach, with specialists in rehabilitation medicine, neurology, neurosurgery, and therapy. It provides surgical and non-surgical interventions for patients who have not responded to medications and conventional therapy. The clinic is a key part of Sidra Medicine's commitment to pioneering pediatric neurology care. Adam was one of the young patients who underwent the groundbreaking Intraventricular Baclofen Therapies at Sidra Medicine. Speaking about the impact of the treatment, Adam's mother said: "Before the surgery, Adam's condition affected nearly every part of his limbs moved constantly, making it difficult for him to concentrate, rest, or participate in school like other children his age." "After his surgery at Sidra Medicine and thanks to the Movement Disorders Clinic, Adam's movements began to settle, and he gained a level of control we had not seen in years. These small improvements transformed how he interacts with the world. It has brought hope back into our home, and I truly believe this procedure and the supporting rehabilitative support can help many more children like Adam," she added. Sidra Medicine's Neurosurgery Department specializes in treating a wide range of neurological conditions, including hydrocephalus, congenital abnormalities, brain and spinal tumors, epilepsy, craniofacial disorders, and spinal conditions. The hospital's use of cutting-edge technology, combined with a patient-centered approach, ensures that children receive world-class care tailored to their individual needs.
Business Upturn
14-05-2025
- Business
- Business Upturn
Piramal Pharma Q4FY25 results: Net profit jumps 52% YoY to Rs 154 crore; revenue up 8% to Rs 2,754 crore
Piramal Pharma Limited (PPL) reported a robust financial performance for the fiscal year ended March 31, 2025, with net profit rising over 411% to ₹91 crore, as compared to ₹18 crore in FY24. The growth was driven by strong momentum in its Contract Development and Manufacturing Organization (CDMO) business and operational efficiency across verticals. The company's revenue from operations stood at ₹9,151 crore, marking a 12% year-on-year growth, while EBITDA increased by 15% to ₹1,580 crore. EBITDA margin remained steady at 17%. For the fourth quarter (Q4FY25), revenue rose 8% YoY to ₹2,754 crore, with net profit at ₹154 crore, up from ₹101 crore in the same period last year. CDMO leads the performance; quality track record maintained The CDMO segment, which includes commercial manufacturing of on-patent molecules, clocked a 15% annual revenue growth to ₹5,447 crore. The business benefited from increased innovation-related work, which rose to 54% of CDMO revenues, and over 50% YoY growth in commercial revenues. The company cleared 36 regulatory inspections and 165 customer audits in FY25 without any major observations, reinforcing its zero OAI (Official Action Indicated) status maintained since 2011. Strong showing in generics and consumer healthcare The Complex Hospital Generics (CHG) business, with revenue of ₹2,633 crore, saw a notable boost from inhalation anesthetics and Baclofen. The company retained its #1 position in the US market for Sevoflurane, with a 44% share. The India Consumer Healthcare (ICH) segment crossed a strategic revenue milestone of ₹1,000 crore, with power brands contributing 49% of total ICH revenue. The company launched 21 new products and 31 new SKUs during the year, and e-commerce sales surged 39% YoY. Balance sheet healthy; net debt under control PPL maintained a Net Debt to EBITDA ratio of 2.7x, well below its previous 5.6x level. Net debt declined to ₹4,199 crore, from ₹3,932 crore in FY24. The company also reported a total equity of ₹8,125 crore. Looking ahead: Innovation and scale Chairperson Nandini Piramal said FY25 was 'a steady year for the company,' highlighting performance across all business segments and reiterating the company's ambition to become a $2 billion revenue company with 25% EBITDA margins and high return on capital employed (ROCE). 'We crossed $1 billion in revenues with 12% YoY growth and 5x increase in net profits. Our focus on innovation, operational excellence, and expansion in the US and emerging markets has placed us on a strong trajectory for sustainable growth,' she added.
Associated Press
11-04-2025
- Business
- Associated Press
Nexus Pharmaceuticals Launches Baclofen Injection Refill Kit
LINCOLNSHIRE, Ill.--(BUSINESS WIRE)--Apr 11, 2025-- Nexus Pharmaceuticals, LLC announces the launch of their Baclofen Injection Refill Kit. Nexus' kit will be the only one on the market that offers a vial presentation. 'We are proud to be supplying healthcare systems with not only a life-changing drug, such as Baclofen, but also with a convenience kit to deliver the medication in a safe, accommodating, and timely fashion,' says Omair Ahmed, Chief Operating Officer at Nexus. 'This kit will ease the lives of those living with long-term severe spasticity conditions.' Baclofen Injection Refill Kits are available now. Order through your Wholesaler today or from Customer Service at (888) 806-4606. Unit of Sale NDC: 14789-0161-01 About Nexus Pharmaceuticals, LLC: Nexus Pharmaceuticals, LLC., a US-based healthcare company, specializes in innovative processes to make difficult-to-manufacture specialty and generic drugs that are easier to use, less labor intensive, and more streamlined in practice. Nexus ensures that its high-quality drug products fulfill a critical unmet medical need and deliver dependable life-saving treatment options when and where they're needed most. View source version on CONTACT: Grace Conroy [email protected] 847-527-7490 KEYWORD: UNITED STATES NORTH AMERICA ILLINOIS INDUSTRY KEYWORD: HEALTH MANUFACTURING OTHER SCIENCE GENERAL HEALTH OTHER MANUFACTURING SCIENCE PHARMACEUTICAL SOURCE: Nexus Pharmaceuticals, LLC Copyright Business Wire 2025. PUB: 04/11/2025 01:43 PM/DISC: 04/11/2025 01:44 PM
Yahoo
07-02-2025
- Business
- Yahoo
Cosmos Health Secures 10-Year Long-Term Contract Manufacturing Order from Provident Pharmaceuticals for 4 Additional Products, Totaling 8 Million Packs, Significantly Expanding High-Margin Revenue Backlog and Cash Flow Visibility
CHICAGO, IL / / February 7, 2025 / Cosmos Health Inc. ("Cosmos Health" or the "Company'') (NASDAQ:COSM), a diversified, vertically integrated global healthcare group engaged in innovative R&D, owner of proprietary pharmaceutical and nutraceutical brands, manufacturer and distributor of healthcare products, and operator of a telehealth platform, announced today that its wholly owned subsidiary, Cana Laboratories ("Cana"), has entered into a new long-term ten-year contract manufacturing agreement with Provident Pharmaceuticals ("Provident"), a specialty pharmaceutical company, to produce four pharmaceutical products. These include Miorelique®, BE Union F.C., and two variations of Certorun, with a total production volume of 800,000 packs per year, or 8,000,000 packs over the ten-year period. Details of the Agreement The agreement covers the production of Miorelique®, an oral solution containing the active ingredient Baclofen, with an annual production volume of 200,000 packs. This product follows Lioresal as the reference drug, a well-established muscle relaxant used to treat spasticity. It also includes the production of BE Union F.C. tablets, formulated with Thiamine, Pyridoxine, and Cyanocobalamin, with an annual production volume of 400,000 packs. These tablets are developed with Neurobion as the reference drug, a vitamin B-complex supplement commonly used for neuropathy and nerve health support. Additionally, the agreement covers the production of Certorun capsules, available in 50 mg and 100 mg formulations, containing the active ingredient Sertraline, with a combined annual production volume of 200,000 packs. This product follows Zoloft as the reference drug, an antidepressant widely prescribed for mood and anxiety disorders. Greg Siokas, CEO of Cosmos Health, stated: "We are very pleased to expand our already successful collaboration with Provident, further accelerating the growth of our contract manufacturing business at Cana's state-of-the-art facilities. These additional orders from Provident underscore our capabilities, and we remain well-positioned to accommodate further contract manufacturing opportunities that contribute to stable, long-term, high-margin cash flows for Cosmos. Cana is currently operating with two shifts and has the ability to expand to three shifts, enabling the Company to operate around the clock to meet increased demand." About Provident Pharmaceuticals Provident, established in 2012, is a privately held specialty pharmaceutical company focused on commercializing and marketing niche and legacy pharmaceutical products and medical devices. Operating in both private and public sectors in Greece, it ensures high-quality, therapeutically valuable products, adhering to European standards. Provident offers comprehensive services, including sales, marketing, regulatory support, market access, and distribution. As market leaders in muscle spasticity and strong performers in HA for joints, oncology, and alimentary tract/metabolism, its mission is to provide innovative, high-quality medicines. The product portfolio spans cardiovascular, central nervous system, oncology, vitamins, medical devices, and veterinary products. About Cosmos Health Inc. Cosmos Health Inc. (Nasdaq:COSM), incorporated in 2009 in Nevada, is a diversified, vertically integrated global healthcare group. The Company owns a portfolio of proprietary pharmaceutical and nutraceutical brands, including Sky Premium Life®, Mediterranation®, bio-bebe®, C-Sept® and C-Scrub®. Through its subsidiary Cana Laboratories S.A., licensed under European Good Manufacturing Practices (GMP) and certified by the European Medicines Agency (EMA), it manufactures pharmaceuticals, food supplements, cosmetics, biocides, and medical devices within the European Union. Cosmos Health also distributes a broad line of pharmaceuticals and parapharmaceuticals, including branded generics and OTC medications, to retail pharmacies and wholesale distributors through its subsidiaries in Greece and the UK. Furthermore, the Company has established R&D partnerships targeting major health disorders such as obesity, diabetes, and cancer, enhanced by artificial intelligence drug repurposing technologies, and focuses on the R&D of novel patented nutraceuticals, specialized root extracts, proprietary complex generics, and innovative OTC products. Cosmos Health has also entered the telehealth space through the acquisition of ZipDoctor, Inc., based in Texas, USA. With a global distribution platform, the Company is currently expanding throughout Europe, Asia, and North America, and has offices and distribution centers in Thessaloniki and Athens, Greece, and in Harlow, UK. More information is available at as well as LinkedIn and X. Forward-Looking Statements With the exception of the historical information contained in this news release, the matters described herein, may contain forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. Statements preceded by, followed by, or that otherwise, include the words "believes," "expects," "anticipates," "intends," "projects," "estimates," "plans" and similar expressions or future or conditional verbs such as "will," "should," "would," "may" and "could", are generally forward-looking in nature and not historical facts, although not all forward-looking statements include the foregoing. These statements, involve unknown risks and uncertainties that may individually or materially impact the matters discussed, herein for a variety of reasons that are outside the control of the Company, including, but not limited to, the Company's ability to raise sufficient financing to implement its business plan, the impact of the COVID-19 pandemic and the war in Ukraine, on the Company's business, operations and the economy in general, and the Company's ability to successfully develop and commercialize its proprietary products and technologies. Readers are cautioned not to place undue reliance on these forward-looking statements, as actual results could differ materially from those described in the forward-looking statements contained herein. Readers are urged to read the risk factors set forth in the Company's filings with the SEC, which are available at the SEC's website ( The Company disclaims any intention or obligation to update, or revise any forward-looking statements, whether as a result of new information, future events or otherwise. Investor Relations Contact: BDG Communicationscosm@ 207 0971 653 SOURCE: Cosmos Health Inc. View the original press release on ACCESS Newswire Sign in to access your portfolio
